Statistics Collaborative - Design and analysis for biomedical research

PublicationsPublications

Kathryn Tucker

  • Epstein JE, Tewari K, Lyke KE, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 2011; 334:475-480.

  • Downs M, Tucker K, Christ-Schmidt H, Wittes J. Some practical problems in implementing randomization. Clin Trials 2010; 7:235-245.

  • Petersen K, Soutiere SE, Tucker KE, Dainer HM, Mahon RT. Oxygen breathing accelerates decompression from saturation at 40 msw in 70-kg swine. Aviat Space Environ Med 2010; 81:639-645.

  • Cummings J, Spring M, Schwenk R, Ockenhouse C, Kester K, Polhemus M, Walsh D, Yoon I, Prosperi C, Juompan L, Lanar D, Krzych U, Hall B, Ware L, Stewart V, Williams J, Dowler M, Nielsen R, Hillier C, Giersing B, Dubovsky F, Malkin E, Tucker K, Dubois M, Cohen J, Ballou W, Heppner Jr. D. Recombinant liver stage antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental plasmodium falciparum infection. Vaccine 2010; 28:5135-5144.

  • Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG, Jr. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 2009; 4:e5254.
  • Ogutu BR, Apollo OJ, McKinney D, Okoth W, Siangla J, Dubovsky F, Tucker K, Waitumbi JN, Diggs C, Wittes J, Malkin E, Leach A, Soisson LA, Milman JB, Otieno L, Holland CA, Polhemus M, Remich SA, Ockenhouse CF, Cohen J, Ballou WR, Martin SK, Angov E, Stewart VA, Lyon JA, Heppner DG, Withers MR. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 2009; 4:e4708.
  • Malkin E, Hu J, Li Z, Chen Z, Bi X, Reed Z, Dubovsky F, Liu J, Wang Q, Pan X, Chen T, Giersing B, Xu Y, Kang X, Gu J, Shen Q, Tucker K, Tierney E, Pan W, Long C, Cao Z. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine 2008; 26:6864-6873.
  • Woodman M, Cooley A, Miller J, Lazarus J, Tucker K, Bykowski T, Botto M, Hellwage J, Wooten RM, Stevenson B. Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection.
    Infect Immun 2007; 75:3131-3139.
  • Stoute JA, Gombe J, Withers MR, Siangla J, McKinney D, Onyango M, Cummings JF, Milman J, Tucker K, Soisson L, Stewart VA, Lyon JA, Angov E, Leach A, Cohen J, Kester KE, Ockenhouse CF, Holland CA, Diggs C, Wittes J, Heppner DG. Phase I randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. Vaccine 2007; 25:176-184.
  • Thera M, Doumbo O, Coulibaly D, Diallo D, Sagara I, Dicko A, Diemert D, Heppner D, Stewart V, Angov E, Soisson L, Leach A, Tucker K, Lyke K, Plowe C. Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trial. PLoS 2006; e34.
  • Withers M, McKinney D, Ogutu B, Waitumbi J, Milman J, Apollo O, Allen O, Tucker K, Soisson L, Diggs C, Leach A, Wittes J, Dubovsky F, Stewart A, Remich S, Cohen J, Ballou R, Holland C, Lyon J, Angov E, Stoute J, Martin S, Heppner D. Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized, phase Ib, dose-escalation trial in Kenyan children. PLoS 2006; e32.
  • Heppner DG, Jr., Kester KE, Ockenhouse CF, Tornieporth N, Ofori O, Lyon JA, Stewart VA, Dubois P, Lanar DE, Krzych U, Moris P, Angov E, Cummings JF, Leach A, Hall BT, Dutta S, Schwenk R, Hillier C, Barbosa A, Ware LA, Nair L, Darko CA, Withers MR, Ogutu B, Polhemus ME, Fukuda M, Pichyangkul S, Gettyacamin M, Diggs C, Soisson L, Milman J, Dubois MC, Garcon N, Tucker K, Wittes J, Plowe CV, Thera MA, Duombo OK, Pau MG, Goudsmit J, Ballou WR, Cohen J. Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. Vaccine 2005; 23:2243-2250.